Hot Movers: MEMC Electronic Materials, Himax Technologies, Horizon Pharma, SolarCity

Lakeway, NY -- (SBWIRE) -- 03/07/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

MEMC Electronic Materials, Inc. (NYSE:WFR) shares jumped 6.30% to $5.57 in the pre-market hour after MEMC Electronic was upgraded by equities researchers at Goldman Sachs from a “neutral” rating to a “buy” rating in a report issued today. The firm currently has a $6.50 target price on the stock, up from their previous target price of $4.00.

Additionally, the company, on Mar. 4, announced that the Company's Board of Directors has appointed Randy H. Zwirn as a new independent member of the Board. Mr. Zwirn, 59, is the Chief Executive Officer, Energy Services Division of Siemens AG (NYSE: SI), Energy Sector. He also serves as President and Chief Executive Officer of Siemens Energy, Inc. with regional responsibility for the overall Energy Sector in the Americas.

Is WFR a Strong Buy After The Recent Slump? Let’s Find out Here

Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) shares climbed 20.26% to $4.58. The company announced the Company will attend the 2013 Bank of America Merrill Lynch Taiwan, Technology & Beyond Conference held at the Far Eastern Plaza Hotel in Taipei from March 12th to March 14th, 2013.

Additionally, the company, on Feb. 7, announced that for first quarter of 2013, it expects revenue to decline by high single digit to low teens in percentage, GAAP earnings per share to be between $0.065-$0.075 per diluted ADS and Non-GAAP EPS to be in between $0.07-$0.08 per diluted ADS. Analysts were expecting the Company to report revenue of $177 million and EPS of $0.07 for first quarter of 2013.

Is HIMX a Strong Buying Opportunity After The Recent Slump? Find out Here

Horizon Pharma Inc (NASDAQ:HZNP) shares climbed 10.24% to $2.05 after the company today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for DUEXIS® (ibuprofen/famotidine) for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen administered three times a day and who are at risk of developing non-steroidal anti-inflammatory drug (NSAID) associated gastric and/or duodenal ulcers

Should Investors Consider HZNP After The Recent price Action? Get Free Trend Analysis Here

SolarCity Corp (NASDAQ:SCTY) shares declined 16.55% to $16.09 in the early hour after the company yesterday reported fourth-quarter net loss of $3 million, as compared with net income of $14 million last year. On a per share basis, net loss for the quarter was $1.10, compared with net income of $0.24 in the prior year. The company said revenues for the quarter rose to $25.3 million from $20.7 million a year ago. Analysts estimated a loss of $0.44 per share on revenues of $36.67 million for the quarter.

Get latest News, Updates on SCTY Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.